Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 22, 2005. The report details corporate actions regarding share repurchases and updates on directors' interests in the company's ordinary shares.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes and share ownership data.
- Share Repurchase Price: 1,227.4854 pence per share.
- Treasury Shares Held: 81,093,000 shares (post-transaction).
- Shares in Issue: 5,859,262,609 shares (excluding treasury shares).
- US Retirement Fund ADRs: 18,392,380 shares (average price $48.48).
Material Changes
The primary material change reported is the execution of a share buyback program authorized by shareholders at the May 17, 2004 Annual General Meeting.
- Buyback Execution: On March 21, 2005, the company purchased 1,200,000 ordinary shares to be held in treasury.
- Director Share Transfer: On March 18, 2005, Director Mr. J D Coombe transferred 50,000 shares to his wife, Mrs. G A Coombe.
- Retirement Fund Movement: The GlaxoSmithKline US Retirement Savings Plan saw a reduction in ADR holdings from 18,472,029 to 18,392,380 due to fund movements on March 17, 2005.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a statutory disclosure of specific transactions.
Investor Verification Checklist
- Verify the total number of treasury shares held (81,093,000) against the company's latest capitalization table.
- Confirm the remaining authorization for share buybacks under the May 2004 shareholder mandate.
- Review the impact of the 1,200,000 share repurchase on earnings per share (EPS) in the next quarterly report.
- Check subsequent filings for further changes in the US Retirement Savings Plan holdings.